MA30779B1 - Comprimes pediatriques de capecitabine - Google Patents

Comprimes pediatriques de capecitabine

Info

Publication number
MA30779B1
MA30779B1 MA31762A MA31762A MA30779B1 MA 30779 B1 MA30779 B1 MA 30779B1 MA 31762 A MA31762 A MA 31762A MA 31762 A MA31762 A MA 31762A MA 30779 B1 MA30779 B1 MA 30779B1
Authority
MA
Morocco
Prior art keywords
capecitabine
less
pharmaconurec
delicant
crospovidone
Prior art date
Application number
MA31762A
Other languages
English (en)
Inventor
Maria Oksana Bachynsky
Martin Howard Infeld
Mohammad Rashed
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30779(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30779B1 publication Critical patent/MA30779B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE PELLICULÉE COMPRENANT DE LA 5'-DÉSOXY-5-FLUORO-N-[(PENTYLOXY)CARBONYL]CYTIDINE (CAPÉCITABINE) ET AU MOINS UN DÉLITANT SÉLECTIONNÉ DANS LE GROUPE CONSTITUÉ DE LA CROSPOVIDONE (TAILLE DES PARTICULES <15-400 µM), DE LA CROSCARMELLOSE SODIQUE, DU GLYCOLATE D'AMIDON SODIQUE, DE L'HYDROXYPROPYLCELLULOSE FAIBLEMENT SUBSTITUÉE, DU PHARMABURST C OU DE N'IMPORTE QUELLE ASSOCIATION DE CEUX-CI, AINSI QUE D'AUTRES EXCIPIENTS ACCEPTABLES DU POINT DE VUE PHARMACEUTIQUE POUR FORMER UN COMPRIMÉ SE DÉLITANT RAPIDEMENT. CE COMPRIMÉ SE DÉLITE DANS DE L'EAU À 37°C DANS UN APPAREIL DE DÉLITEMENT SELON LA PHARMACOPÉE USP EN MOINS DE 2 MINUTES, DE PRÉFÉRENCE EN MOINS DE 1 MINUTE, ET A UNE DURETÉ DE 8-13 UNITÉS DE STRONG-COBB.
MA31762A 2006-10-06 2009-04-06 Comprimes pediatriques de capecitabine MA30779B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85017406P 2006-10-06 2006-10-06
US95155707P 2007-07-24 2007-07-24

Publications (1)

Publication Number Publication Date
MA30779B1 true MA30779B1 (fr) 2009-10-01

Family

ID=39186803

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31762A MA30779B1 (fr) 2006-10-06 2009-04-06 Comprimes pediatriques de capecitabine

Country Status (31)

Country Link
US (2) US20080085310A1 (fr)
EP (1) EP2073791B1 (fr)
JP (1) JP5330248B2 (fr)
KR (1) KR101177730B1 (fr)
CN (1) CN101522168B (fr)
AR (1) AR063138A1 (fr)
AT (1) ATE492267T1 (fr)
AU (1) AU2007304293A1 (fr)
BR (1) BRPI0719241A2 (fr)
CA (1) CA2664922C (fr)
CL (1) CL2007002875A1 (fr)
CO (1) CO6150122A2 (fr)
CR (1) CR10668A (fr)
CY (1) CY1111223T1 (fr)
DE (1) DE602007011475D1 (fr)
DK (1) DK2073791T3 (fr)
HK (1) HK1135905A1 (fr)
HR (1) HRP20110113T1 (fr)
IL (1) IL197767A0 (fr)
MA (1) MA30779B1 (fr)
MX (1) MX2009003317A (fr)
MY (1) MY145637A (fr)
NO (1) NO20090980L (fr)
NZ (1) NZ575280A (fr)
PE (1) PE20081106A1 (fr)
PL (1) PL2073791T3 (fr)
PT (1) PT2073791E (fr)
RU (1) RU2455979C2 (fr)
SI (1) SI2073791T1 (fr)
TW (1) TW200825096A (fr)
WO (1) WO2008040665A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110027374A1 (en) * 2008-12-16 2011-02-03 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TWI455733B (zh) * 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
CN102516338B (zh) * 2011-12-09 2014-04-02 海南锦瑞制药股份有限公司 一种卡培他滨化合物、其药物组合物及其制备方法
CN103156877B (zh) * 2011-12-13 2015-11-25 深圳海王药业有限公司 一种卡培他滨速释微丸及其制备方法
CN102988320B (zh) * 2012-12-13 2014-04-16 哈药集团技术中心 一种卡培他滨分散片及其制备方法
CN104739800A (zh) * 2015-02-03 2015-07-01 吉林修正药业新药开发有限公司 一种卡培他滨片组合物及其制备方法
JP6673798B2 (ja) * 2016-10-12 2020-03-25 日本化薬株式会社 カペシタビンを有効成分とするフィルムコート医薬製剤
JP6866113B2 (ja) * 2016-11-01 2021-04-28 日本化薬株式会社 カペシタビンを有効成分とする医薬製剤
JP6792418B2 (ja) * 2016-11-08 2020-11-25 日本化薬株式会社 カペシタビンを有効成分とする医薬製剤の製造方法
JP7170554B2 (ja) 2019-02-06 2022-11-14 ゼネラル株式会社 感熱転写媒体
BR112022022796A2 (pt) * 2020-05-19 2022-12-13 Cellix Bio Private Ltd Composição farmaceuticamente aceitável

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
CA1327358C (fr) * 1987-11-17 1994-03-01 Morio Fujiu Derives fluorocytidine
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (fr) * 1992-12-18 1995-08-21 Hoffmann La Roche
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
JPH0971523A (ja) * 1995-09-07 1997-03-18 Riyuukakusan:Kk 口腔内で崩壊性の速い錠剤
JP2002505269A (ja) * 1998-03-06 2002-02-19 エウランド インターナショナル ソシエタ ペル アチオニ 急速崩壊錠剤
RU2135169C1 (ru) * 1998-12-02 1999-08-27 Государственное предприятие Казанское производственное химико-фармацевтическое объединение "Татхимфармпрепараты" Противовоспалительное, болеутоляющее, жаропонижающее лекарственное средство и способ его получения
JP2000273039A (ja) * 1999-01-20 2000-10-03 Taisho Pharmaceut Co Ltd 口腔内崩壊性組成物
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2790387B1 (fr) * 1999-03-01 2001-05-18 Prographarm Laboratoires Comprime orodispersible presentant une faible friabilite et son procede de preparation
AU4278301A (en) * 2000-03-27 2001-10-08 Kyowa Hakko Kogyo Co. Ltd. Easy-to-take granule
KR20030081472A (ko) * 2001-03-06 2003-10-17 교와 핫꼬 고교 가부시끼가이샤 구강내 속붕괴성 제제
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
DE102004028940A1 (de) * 2004-06-15 2006-01-12 Krka Tovarna Zdravil, D.D. Oral zerfallende pharmazeutische Zusammensetzung, die Risperidon enthält
ES2327195B1 (es) * 2005-04-12 2010-07-09 Elan Pharma International Limited Composiciones de liberacion modificada que comprenden un derivado de fluorocitidina para el tratamiento del cancer.

Also Published As

Publication number Publication date
EP2073791B1 (fr) 2010-12-22
BRPI0719241A2 (pt) 2014-07-15
WO2008040665A2 (fr) 2008-04-10
CO6150122A2 (es) 2010-04-20
MY145637A (en) 2012-03-15
IL197767A0 (en) 2009-12-24
NZ575280A (en) 2012-03-30
CR10668A (es) 2009-04-29
PL2073791T3 (pl) 2011-05-31
PT2073791E (pt) 2011-01-21
DE602007011475D1 (de) 2011-02-03
SI2073791T1 (sl) 2011-04-29
CN101522168A (zh) 2009-09-02
AR063138A1 (es) 2008-12-30
CA2664922C (fr) 2015-06-30
HK1135905A1 (en) 2010-06-18
US20080085310A1 (en) 2008-04-10
HRP20110113T1 (hr) 2011-03-31
AU2007304293A1 (en) 2008-04-10
KR101177730B1 (ko) 2012-09-07
RU2455979C2 (ru) 2012-07-20
CY1111223T1 (el) 2015-06-11
PE20081106A1 (es) 2008-09-17
EP2073791A2 (fr) 2009-07-01
US20150044287A1 (en) 2015-02-12
CL2007002875A1 (es) 2008-01-25
DK2073791T3 (da) 2011-01-31
TW200825096A (en) 2008-06-16
NO20090980L (no) 2009-03-31
CA2664922A1 (fr) 2008-04-10
CN101522168B (zh) 2011-09-28
ATE492267T1 (de) 2011-01-15
MX2009003317A (es) 2009-04-09
RU2009116816A (ru) 2010-11-20
KR20090045948A (ko) 2009-05-08
JP2010505791A (ja) 2010-02-25
JP5330248B2 (ja) 2013-10-30
WO2008040665A3 (fr) 2008-06-19

Similar Documents

Publication Publication Date Title
MA30779B1 (fr) Comprimes pediatriques de capecitabine
CN104039319B (zh) 用于治疗hcv的组合物和方法
MA28748B1 (fr) Applications galeniques de melanges auto-emulsionnants d&#39;excipients lipidiques
TNSN00252A1 (fr) Compositions pharmaceutiques engendrant des concentrations accrues de medicaments
ATE521343T1 (de) Im mund zerfallende zusammensetzungen von rasagilin
Naramoto et al. Effects of an ethanol extract of Brazilian green propolis on human cytochrome P450 enzyme activities in vitro
MA54411B1 (fr) Compositions contenant de l&#39;ibrutinib
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
MA30807B1 (fr) Compositions pharmaceutiques.
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
WO2005065646A3 (fr) Compositions medicamenteuses et formes pharmaceutiques
MA33295B1 (fr) Nouvelle formulation de diclofénac
WO2006099379A3 (fr) Derives de benzazole, compositions et methodes d&#39;utilisation des derives comme inhibiteurs de la b-secretase
MA35662B1 (fr) Administration d&#39;un inhibiteur d&#39;enzyme activant nedd8 et agent d&#39;hypométhylation
FR2949044B1 (fr) Composition comprenant une fraction d&#39;insaponifiable
BRPI0507747A (pt) medicamento com base em planta para o tratamento da hepatite c
MA30325B1 (fr) Composes qui potentialisent le recepteur ampa et leurs utilisations en medecine
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l&#39;indolylmaleimide
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
MA29451B1 (fr) Association entre la ferroquine et un derive d&#39;artemisinine pour le traitement du paludisme
MA28237A1 (fr) Composition pharmaceutique de vinflunine destinee a une administration parenterale, procede de preparation et utilisation
MA34670B1 (fr) Inhibiteurs de l&#39;apoptose et leurs utilisations
US20190321377A1 (en) Combination therapy for nonalcoholic steatohepatitis (nash) and liver fibrosis
JP2024045760A (ja) 医薬組成物
MA37953A1 (fr) Formulation de capsule composite pharmaceutique comprenant de l&#39;irbésartan et un inhibiteur de la hmg-coa réductase